## Edgar Filing: Weyer Christian - Form 4

Weyer Christi Form 4	ian										
April 03, 2019	9										
								OMB AF	PROVAL		
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287	
Check this if no longe subject to Section 16 Form 4 or Form 5	er <b>STATE</b> 5.	x STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
obligation: may contin <i>See</i> Instruct 1(b).	s Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type Ro	esponses)										
]			2. Issuer Name <b>and</b> Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS, INC. [ICPT]					5. Relationship of Reporting Person(s) to Issuer			
								(Check all applicable)			
	(First) CEPT EUTICALS, IN ARDS, FLOOI		3. Date of (Month/D 04/01/20	-	ansaction			X Officer (give below) EVP, Reser	title Othe below) arch & Develop		
			4. If Ame	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
NEW YORK	K, NY 10001		Filed(Mor	nth/Day/Year	)			Applicable Line) _X_Form filed by C Form filed by M Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Securi	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
	2. Transaction Da (Month/Day/Year	r) Execution any		3. Transactic Code (Instr. 8)		sposed	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	04/01/2019			Code V F	Amount 46 (1)	(D) D	Price \$ 111.5	19,061	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Weyer Christian - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships							
	Director	10% Owner	Officer	Other					
Weyer Christian C/O INTERCEPT PHARMACEUTICALS, IN 10 HUDSON YARDS, FLOOR 37 NEW YORK, NY 10001	IC.		EVP, Research & Development						
Signatures									
/s/ John C. Duncanson, as attorney-in-fact	04/03/2019								
Signature of Reporting Person	Date								
Explanation of Responses									

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.